Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1

Most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have exhausted their treatment options and are deemed palliative. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has recently been introduced as a new option for these patients. Lisocabtagene maraleucel...

Descripción completa

Detalles Bibliográficos
Autores principales: Salles, Gilles, Spin, Paul, Liu, Fei Fei, Garcia, Jacob, Kim, Yeonhee, Hasskarl, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189990/
https://www.ncbi.nlm.nih.gov/pubmed/33970454
http://dx.doi.org/10.1007/s12325-021-01756-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189990/
https://www.ncbi.nlm.nih.gov/pubmed/33970454
http://dx.doi.org/10.1007/s12325-021-01756-0

Ejemplares similares